Result of AGM

10^th May 2017

EKF Diagnostics Holdings plc
("EKF", the "Company")

Result of AGM

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

EKF Diagnostics Holdings plc	www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman	Tel: 029 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO


N+1 Singer (Nomad & Broker)	Tel: 020 7496 3000
Alex Price / Shaun Dobson / Ali Laughton-Scott


Walbrook PR Limited	Tel: 020 7933 8780 or
Paul McManus / Lianne Cawthorne	Mob: 07980 541 893 / 07584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

MEDLAB Dubai - Feb 2020

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.

AIM Awards 2019

EKF Diagnostics was delighted to win the AIM Transaction of the Year Award at the AIM Awards 2019.

New R&D facility in Head Office

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core markets and support other global diagnostics R&D facilities

Medica 2019

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

EKF announces the availability of a liquid, enzymatic test for glycated albumin (GA) that was recently FDA cleared for sales in the U.S. GA, used for intermediate term monitoring of glycemic control in diabetes patients, will be showcased at the 2019 AACC.